April 26, 2011 -- Just before the company completes its $1.8 billion Hong Kong IPO, Shanghai Pharmaceuticals Holding reported its Q1 net income more than doubled, rising 107% to 849 million RMB ($130 million). The big earnings jump came on a comparatively modest 27% increase in sales, which hit 11.9 billion RMB ($1.8 billion). The company is definitely on a roll: earnings were up 90% in 2010 over the year earlier. No particular mystery about this. To make itself more attractive to investors, Shanghai Pharma has been in a restructuring frenzy during the last two years. More details....
Stock Symbol: (SHA: 601607)
